Drug study to reduce heart thickening in aortic stenosis
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a combination of two drugs usually used for heart failure or diabetes can reduce thickening and scarring of the heart muscle in people with severe aortic stenosis after their valve is replaced. The goal is to help the heart recover more fully after the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have severe narrowing of the heart's main valve (aortic stenosis) that causes symptoms.
- You must be scheduled for surgery or a less invasive procedure to replace the heart valve (known as SAVR or TAVI).
- Your heart's pumping strength (ejection fraction) must be 40% or higher.
- You must not be taking certain heart failure or diabetes medicines like spironolactone or empagliflozin.
- Your kidney function must be good (not below a certain level).
- You must not have diabetes requiring insulin, and you must be able to have an MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether angiotensin receptor blocker (ARB) blood pressure medication helps people with mild to moderate aortic stenosis (a narrowing of the heart’s main valve). It looks at safety and whether the treatment offers benefit for your heart and blood flow.
This trial tests whether remote monitoring with regular MRI scans can help manage aortic stenosis (a narrowed heart valve) in patients who don't have symptoms yet. The goal is to catch changes early and potentially delay or avoid the need for surgery.
This study looks at how heart mechanics, blood markers, and frailty relate to symptoms and heart measurements in people with aortic stenosis (a stiff, narrowed heart valve). It may help doctors better understand who is at higher risk and how disease changes over time.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.